Gainers

• Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million.
• Medicus Pharma (NASDAQ:MDCX) stock rose 7.46% to $0.4. The market value of their outstanding shares is at $23.0 million.
• SANUWAVE Health (NASDAQ:SNWV) shares rose 6.57% to $12.0. The market value of their outstanding shares is at $100.4 million.
• Tempest Therapeutics (NASDAQ:TPST) shares moved upwards by 5.74% to $1.04. The company's market cap stands at $15.5 million.
• Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 5.24% to $21.69. The market value of their outstanding shares is at $1.2 billion.
• Impact BioMedical (AMEX:IBO) stock increased by 4.75% to $0.48. The market value of their outstanding shares is at $47.6 million.

Losers

• BNB Plus (NASDAQ:BNBX) stock declined by 18.3% to $0.13 during Monday's after-market session. The market value of their outstanding shares is at $2.7 million.
• MBX Biosciences (NASDAQ:MBX) stock decreased by 13.4% to $52.0. The company's market cap stands at $2.9 billion.
• China Pharma Holding (AMEX:CPHI) shares fell 11.19% to $0.56. The company's market cap stands at $23.0 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) shares fell 8.78% to $0.7. The market value of their outstanding shares is at $36.9 million.
• Matinas BioPharma Hldgs (AMEX:MTNB) shares declined by 8.34% to $0.44. The market value of their outstanding shares is at $4.8 million.
• NewGenIvf Group (NASDAQ:NIVF) stock decreased by 7.81% to $1.3. The market value of their outstanding shares is at $4.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.